Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of 14C-VX-407 in Healthy Subjects
NCT07868926Phase 1Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Vertex Pharmaceuticals. Primary endpoints: Amount of Radioactivity Excreted, Terminal Phase Rate Constant and 15 more. Started Oct 2026; status: recruiting.
02
Drugs
VX-407
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07868926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868926.